Key result
GW0742 pretreatment ameliorated Angiotensin II-induced cardiomyocyte hypertrophy and inhibited the expression of inflammatory cytokines MMP9, MMP2, and IL-1beta in vitro.
Why the study?
Does GW0742 prevent Angiotensin II-induced cardiac hypertrophy in neonatal rat cardiomyocytes?
Population
In vitro cardiomyocyte hypertrophy model from neonatal rats induced with Angiotensin II (Ang II 1 micromol x…
Comparison
GW0742 (10 micromol.L), an agonist of… vs Ang II stimulation without GW0742 pretreatment
Design
Preclinical
Follow-up
48 hours (pretreatment)
Authors
Loading...
Supports PPARβ/δ agonism in rat cardiomyocyte hypertrophy; hypothesis-generating, requires in vivo and human validation before any clinical consideration.
Does GW0742 prevent Angiotensin II-induced cardiac hypertrophy in neonatal rat cardiomyocytes?
GW0742, a PPARbeta/delta agonist, exerts a beneficial effect on Angiotensin II-induced cardiac hypertrophy and related inflammatory responses in vitro.
Sheng et al. (2008) studied Angiotensin II-induced cardiac hypertrophy. GW0742 vs. Angiotensin II stimulation alone was evaluated on Cardiomyocyte hypertrophy (surface area, ANP/BNP mRNA, 3H-leucine incorporation). GW0742 pretreatment ameliorated Angiotensin II-induced cardiomyocyte hypertrophy and inhibited the expression of inflammatory cytokines MMP9, MMP2, and IL-1beta in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: